SCHEMBL3705033

SCHEMBL3705033

Cc1cnc2[nH]cc(C(=O)c3cccc(N)c3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.47
NPC1 O15118 1/20 0.47
MITF O75030 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
CYP3A4 P08684 1/20 0.46
BRD4 O60885 2/20 0.46
BRAF P15056 1/20 0.45
CYP2C19 P33261 1/20 0.43
NEK2 P51955 3/20 0.42
PBRM1 Q86U86 1/20 0.42
AXL P30530 4/20 0.42
KIT P10721 1/20 0.41
PAK1 Q13153 2/20 0.41
NTRK1 P04629 4/20 0.41
DYRK1A Q13627 2/20 0.40
PIK3CA P42336 1/20 0.40
CDC7 O00311 1/20 0.40
PLK4 O00444 1/20 0.40
CHEK1 O14757 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3710853 0.88 NEK2 (0.50) AAK1CYP3A4BRD4BRAFCYP2C19
SCHEMBL297306 0.85 BRAF (0.45) AAK1NPC1MITFLMNAPOLB
SCHEMBL298022 0.85 PAK1 (0.48) AAK1NPC1MITFLMNAPOLB
SCHEMBL297839 0.85 AAK1 (0.45) AAK1NPC1MITFLMNAPOLB
SCHEMBL3698741 0.85 AAK1 (0.53) AAK1NPC1MITFLMNAPOLB
SCHEMBL858632 0.81 NTRK1 (0.64) AAK1NEK2AXLKITPAK1
SCHEMBL299080 0.81 XDH (0.48) AAK1NPC1CYP3A4BRD4BRAF
SCHEMBL7877599 0.81 AAK1 (0.42) AAK1NPC1MITFLMNAPOLB
SCHEMBL856986 0.81 NEK2 (0.60) BRD4NEK2PBRM1AXLNTRK1
SCHEMBL416155 0.81 AAK1 (0.53) AAK1BRAFNEK2AXLKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF AAK1 247/4885NPC1 4710/4885MITF 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.